The medtech company announces that Business Finland has granted them an R&D loan amounting to approximately EUR 1 million for the development of a next-generation user interface (GUI) for the Navigated Brain Therapy (NBT) System indicated for the treatment of Major Depressive Disorder (MDD) and chronic neuropathic pain.
To enable extensive therapeutic use of the NBT System, the project is a major part of Nexstim’s commercialisation process of its therapeutic products.
The loan is unsecured, and the interest rate is three percentage points below the base interest rate, or at least one percent. The loan period is seven years and the three first three years are amortisation-free. The loan will be repaid in annual instalments.